NCT00567918View on ClinicalTrials.gov

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
KeratoconjunctivitisConjunctivitis
Interventions
DRUG

FK506

Ophthalmic suspension

Trial Locations (8)

Unknown

Ehime

Hokkaido

Kagoshima

Kochi

Miyazaki

Osaka

Tochigi

Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY